Former FDAer joins Foley & Lardner
This article was originally published in The Tan Sheet
Executive Summary
Former FDA counsel David Rosen joins Washington-D.C. law firm Foley & Lardner as partner in the Life Sciences Industry Team. Rosen was most recently a partner at DLA Piper Rudnick Gray Cary; during his tenure at FDA, Rosen served as regulatory counsel and division of generic drugs review support branch chief. Pharmaceutical patent litigator Steven Maddox also joins Foley & Lardner's intellectual property and life sciences departments from Piper Rudnick...
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.